[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

KR970025614A - Vasodilator composition - Google Patents

Vasodilator composition Download PDF

Info

Publication number
KR970025614A
KR970025614A KR1019960053685A KR19960053685A KR970025614A KR 970025614 A KR970025614 A KR 970025614A KR 1019960053685 A KR1019960053685 A KR 1019960053685A KR 19960053685 A KR19960053685 A KR 19960053685A KR 970025614 A KR970025614 A KR 970025614A
Authority
KR
South Korea
Prior art keywords
ginsenosides
ginseng
plants
organic solvent
ginsenoside
Prior art date
Application number
KR1019960053685A
Other languages
Korean (ko)
Other versions
KR100201585B1 (en
Inventor
김낙두
박만기
박정일
김종문
강수연
김왕유
Original Assignee
김낙두
손경식
박만기
제일제당 주식회사
박정일
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김낙두, 손경식, 박만기, 제일제당 주식회사, 박정일 filed Critical 김낙두
Priority to PCT/KR1996/000207 priority Critical patent/WO1997018824A1/en
Priority to JP9519605A priority patent/JP2000502994A/en
Priority to EP96939357A priority patent/EP0873131B1/en
Priority to AT96939357T priority patent/ATE275408T1/en
Priority to AU76563/96A priority patent/AU7656396A/en
Priority to DE69633345T priority patent/DE69633345T2/en
Publication of KR970025614A publication Critical patent/KR970025614A/en
Priority to KR1019990002120A priority patent/KR100228510B1/en
Application granted granted Critical
Publication of KR100201585B1 publication Critical patent/KR100201585B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

본 발명은 인삼의 성분중의 하나인 진세노사이드 Rg3및/또는 Rg5를 활성성분으로서 함유하는 혈관이완제 조성물에 관한 것이다. 본 발명에 따르는 조성물의 활성성분인 진세노사이드 Rg3및 Rg5는 내피외존적으로 혈관이완작용을 나타내며, 일반적으로 사포닌 성분과는 달리 내피세포를 파괴하지 않아 용혈적용이나 어독성등의 부작용이 없이 사용할 수 있는 안전한 의약성분이다. 진세노사이드 Rg3및 Rg5는 수삼, 백삼 등의 인삼식물에는 거의 존재하지 않고 홍삼중에 극미량으로만 존재하는 성분으로, 인삼 식물을 110 내지 180℃의 고온에서 0.5 내지 20시간 동안 가열함으로써 그 함량이 현저히 증가한다.The present invention relates to a vasodilator composition comprising ginsenoside Rg 3 and / or Rg 5 as one of the components of ginseng as an active ingredient. Ginsenosides Rg 3 and Rg 5 , the active ingredients of the composition according to the present invention exhibits vascular relaxation in the endothelial and external endothelial, and unlike the saponin component generally does not destroy endothelial cells, so side effects such as hemolysis or fish toxicity A safe pharmaceutical ingredient that can be used without Ginsenosides Rg 3 and Rg 5 are rarely present in ginseng plants such as ginseng and white ginseng, and are present only in trace amounts in red ginseng, and their contents by heating ginseng plants at a high temperature of 110 to 180 ° C. for 0.5 to 20 hours. This increases significantly.

Description

혈관이완제 조성물Vasodilator composition

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 진세노사이드 Rg3는 내피존재하에서 단독투여하였을 때의 혈관이환효과(-●-)를 내피를 제거하고 투여하였을 때(-○-), 내피존재하에서 Rg3를 10-6M의 메틸렌블루(MB)와 병용투여하였을 때(-△-) 및 10-6M의 L-니트로알기니(L-NLA)과 병용투여하였을 때(-▲-)의 혈관이완효과와 비교하여 나타낸 그래프이다,First turning ginsenoside Rg 3 is vascular morbidity when administered alone under the effect of the presence of endothelium, 10 -6 M to 3 Rg under endothelial present when the endothelium was removed and the dose (- - ●) (- - ○) Graphs compared with vasorelaxant effect when combined with methylene blue (MB) (-Δ-) and when combined with 10-6 M of L-nitroalginine (L-NLA) (-▲-) to be,

제2도는 실시예 7에서 제판한 가공 파낙사디올계 사포닌 분획을 내피존재하에서 투여하였을 때(-●-) 및 내피를 제거하여 투여하였을 때의 혈관이완효과를 비교하여 나타낸 그래프이다,FIG. 2 is a graph showing the vascular relaxation effect when the processed panaxanadiol-based saponin fraction produced in Example 7 was administered in the presence of endothelial (-●-) and when the endothelial was removed and administered.

제3도는 HUVEC 세포에 대한 진세노사이드 Rg3와 용매로 사용한 디메틸설폭사이드(DMSO)의 세포독성 실험결과를 나타낸 그래프로 세포에 DMSO를 가하여 배양하였을 때(-○-) 및 진세노사이드 Rg3를 DMSO에 용해시킨 용액을 가하여 배양하였을 때(-∇-)의 세포의 생존율을 비핀하여 나타낸 그래프이다,3 when turning of culture was added to DMSO to cytotoxicity results of dimethyl sulfoxide (DMSO) was used as ginsenoside Rg 3 and a solvent for the HUVEC cells as shown graph the cells (- ○ -), and ginsenosides Rg 3 Is a graph showing the non-pinning of the survival rate of the cells when the solution dissolved in DMSO was cultured (-∇-).

제4도는 진세노사이드 Rg5를 내피 존재하에서 단독투어하였을 때의 혈관이완효과(-○-)-를, 내피를 제거하고 투여하였을 때(-■-), 내피존재하에서 Rg5를 10-6M의 메틸렌블루(MB)와 병용투여하였을 때(-∇-) 및 10-6M의 L-니트로알기닌(L-NLA)과 병용투여하였을 때(-△-)의 혈관이완효과와 비교하여 나타낸 그래프이다,FIG. 4 shows the vasorelaxant effect (-○-)-when ginsenoside Rg 5 alone was administered in the endothelium, and when the endothelium was removed (-■-), Rg 5 was reduced to 10 -6. In comparison with the vasorelaxant effect when combined with methylene blue (MB) of M (-및-) and when combined with L-nitroarginine (L-NLA) of 10 -6 M (-Δ-). It is a graph,

제5도는 HUVEC 세포에 대한 진세노사이드 Rg5와 용매로 사용한 디메틸설폭사이드(DMSO)의 세포독성 실험결과를 나타낸 그래프로서 세포에 DMSO를 가하여 배양하였을 때(-●-) 및 진세노사이드 Rg5를 DMSO에 용해시킨 용액을 가하여 배양하였을 때(-■-)의 세포의 생존율을 비교하여 나타낸 그래프이다.The fifth turning when a graph illustrating the cytotoxicity results of dimethyl sulfoxide (DMSO) was used as ginsenosides Rg 5 and a solvent for the HUVEC cells of culture was added to DMSO to the cells (- ● -), and ginsenosides Rg 5 Is a graph showing the survival rate of cells when (-■-) was cultured by adding a solution dissolved in DMSO.

Claims (9)

활성성분으로서 진세노사이드 Rg3및/또는 Rg5를 함유하는 혈관이완제 조성물.A vasodilator composition comprising ginsenosides Rg 3 and / or Rg 5 as active ingredients. 제1항에 있어서, 활성성분인 진세노사이드 Rg3및/또는 Rg5가 순수한 Rg3및/또는 Rg5이거나, Rg3및/또는 Rg5를 10% 이상 함유하는 인삼 추출물임을 특징으로 하는 혈관이완제 조성물.The blood vessel of claim 1, wherein the active ginsenosides Rg 3 and / or Rg 5 are pure Rg 3 and / or Rg 5 or ginseng extracts containing 10% or more of Rg 3 and / or Rg 5 . Relaxant composition. 제1항에 있어서, 약제학적으로 허용되는 담체와 함께 단위투여형으로 제형화됨을 특징으로 하는 혈관이완제 조성물.The vasodilator composition according to claim 1, which is formulated in a unit dosage form with a pharmaceutically acceptable carrier. 제3항에 있어서, 단위투여형 약제학적으로 제형이 정제, 경질 또는 연질캅셀제, 과립제, 액제, 현탁제, 주사용 용액 또는 혈탁액임을 특징으로 하는 혈관이환제 조성물.The vascular disease composition according to claim 3, wherein the dosage form is a tablet, a hard or soft capsule, a granule, a liquid, a suspension, an injectable solution or a blood solution. 제4항에 있어서 단위투여형이 진세노사이드 Rg3및/또는 Rg5를 10 내지 500mg 함유하도록 제형화됨을 특징으로 하는 혈관이완제 조성물.The vasodilator composition according to claim 4, wherein the unit dosage form is formulated to contain 10 to 500 mg of ginsenosides Rg 3 and / or Rg 5 . 파라스속 식물을 110 내지 180℃의 온도에서 0.5 내지 20시간 동안 가열 처리하고, 수득된 가공인삼을 유기용매로 추출한 후에 추출물을 크로마토그라피 처리하고 진세노사이드 Rg3및/또는 Rg5를 분리수득하는 단계를 포함함을 특징으로 하는 진세노사이드 Rg3및/또는 Rg5를 제조하는 방법.The genus Paras plants were heat treated at a temperature of 110 to 180 ° C. for 0.5 to 20 hours, and the obtained ginseng was extracted with an organic solvent, followed by chromatographic extraction of the extract and obtaining ginsenoside Rg 3 and / or Rg 5 . A process for preparing ginsenosides Rg 3 and / or Rg 5 , characterized in that it comprises a step. 파낙스속 식물을 유기용매로 추출하고, 추출물을 110 내지 180℃에서 0.5 내지 20시간 동안 가열처리한 후에 크로마토그라피 처리하고 진세노사이드 Rg3및/또는 Rg5를 분리 수득하는 단계를 포함함을 특징으로 하는 진세노사이드 Rg3및/또는 Rg5를 제조하는 방법.Extracting plants of Panax genus with an organic solvent, and subjecting the extract to heat treatment at 110 to 180 ° C. for 0.5 to 20 hours, followed by chromatographic treatment to separate and obtain ginsenoside Rg 3 and / or Rg 5 . A process for producing ginsenosides Rg 3 and / or Rg 5 . 파낙스속 식물을 유기용매로 추출하고, 추출물을 50 내지 100℃에서 산으로 처리한 후에 크로마토그라피 처리하고 진세노사이드 Rg3및/또는 Rg5를 분리 수득하는 단계를 포함함을 특징으로 하는 진세노사이드 Rg3및/또는 Rg5를 제조하는 방법.Ginseno comprising the step of extracting the genus Panax plants with an organic solvent, treating the extract with an acid at 50 to 100 ℃, then chromatographic treatment and separating and obtaining the ginsenoside Rg 3 and / or Rg 5 Process for preparing side Rg 3 and / or Rg 5 . 파낙스속 식물을 유기용매로 추출하여 파낙사디온계 분획을 수득하고 이 분획을 110 내지 180℃에서 0.5 내지 20시간 동안 가열처리하여 가공 파낙사디올계 사포닌을 제조하는 방법.A method for preparing a processed panaxidiol-based saponin by extracting a Panax genus plant with an organic solvent to obtain a panaxadione-based fraction, and heat-processing the fraction at 110 to 180 ° C for 0.5 to 20 hours. ※ 참고사항:최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019960053685A 1995-11-22 1996-11-13 Vasodilator composition KR100201585B1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
PCT/KR1996/000207 WO1997018824A1 (en) 1995-11-22 1996-11-20 Vasodilating composition
JP9519605A JP2000502994A (en) 1995-11-22 1996-11-20 Composition of vasorelaxant
EP96939357A EP0873131B1 (en) 1995-11-22 1996-11-20 Processes for preparation of rg3 and rg5 ginsenosides
AT96939357T ATE275408T1 (en) 1995-11-22 1996-11-20 METHOD FOR PRODUCING RG3 AND RG5 GINSENOSIDES
AU76563/96A AU7656396A (en) 1995-11-22 1996-11-20 Vasodilating composition
DE69633345T DE69633345T2 (en) 1995-11-22 1996-11-20 PROCESS FOR THE PREPARATION OF RG3 AND RG5 GINSENOSIDES
KR1019990002120A KR100228510B1 (en) 1995-11-22 1999-01-23 A process for the preparation of ginsenoside Rg3 and/or Rg5

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19950042997 1995-11-22
KR95-42997 1995-11-22
KR101995042997 1995-11-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019990002120A Division KR100228510B1 (en) 1995-11-22 1999-01-23 A process for the preparation of ginsenoside Rg3 and/or Rg5

Publications (2)

Publication Number Publication Date
KR970025614A true KR970025614A (en) 1997-06-24
KR100201585B1 KR100201585B1 (en) 1999-06-15

Family

ID=19435248

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960053685A KR100201585B1 (en) 1995-11-22 1996-11-13 Vasodilator composition

Country Status (2)

Country Link
JP (1) JP3382623B2 (en)
KR (1) KR100201585B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100773275B1 (en) * 2006-05-08 2007-11-05 건국대학교 산학협력단 Therapeutic and prophylaxic agent for cardiovascular diseases comprising ginseng saponins

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100504966B1 (en) * 2003-02-10 2005-08-01 주식회사 바이오사포젠 Antihypertensive constituents of ginseng saponin
KR100740609B1 (en) 2004-06-11 2007-07-18 주식회사 유니젠 Composition having ginsenosides for treating or preventing angiostenosis and restenosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100773275B1 (en) * 2006-05-08 2007-11-05 건국대학교 산학협력단 Therapeutic and prophylaxic agent for cardiovascular diseases comprising ginseng saponins

Also Published As

Publication number Publication date
JP3382623B2 (en) 2003-03-04
KR100201585B1 (en) 1999-06-15

Similar Documents

Publication Publication Date Title
KR100192678B1 (en) Processed ginseng product having an increased pharmacological activity
ATE150974T1 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF SKIN DAMAGE
GB1092269A (en) Hydroxyflavan 3,4-diols and medicaments based thereon
DE60027481T2 (en) Composition for the treatment of chronic venous insufficiency with an extract of leaves of red grapevines
CN102470153A (en) Activity enhancer for oxidized protein hydrolase
Savych et al. Comparative analysis of hypoglycemic activity of herbal mixtures by glucose tolerance tests (message 2)
Savych et al. Determinationof hypoglycemic activity of the herbal mixtures by means of glucose loading tests (message 3)
Sumathi et al. In-vitro anti-inflammatory activity of flower extract of Couroupita guianensis Aubl
KR101834745B1 (en) A manufacturing method of functional powder comprising abundant rutin ingredient
CN114344352B (en) Composition with efficacy of resisting advanced glycosylation end products and application thereof
KR970025614A (en) Vasodilator composition
DE1467800A1 (en) Process for the treatment of plants in particular containing saponin
JP2013241367A (en) Rheumatoid arthritis inhibitor
US6395308B1 (en) Purified extract from Harpagophytum procumbens and/or Harpagophytum zeyheri dence
RU2000120474A (en) PHARMACEUTICAL COMPOSITION POSSESSING ANTITUM ACTIVITY AND METHOD FOR PRODUCING IT
KR19990073622A (en) Manufacture method of drink for white stone extract contain
US6291241B1 (en) Methods for making Hypericum fractions and St. John's Wort products
Gbolade Nigerian Medicinal Plants with Antisnake Venom Activitiy-Review
KR960700064A (en) Prostate Extract Supplemented with Zinc
JP2019216679A (en) Polyphenol-containing extract, polyphenol-containing composition, and food composition as well as producing method thereof, method for improving stability, and method for improving water solubility
CN108853464A (en) A kind of preparation method of ginkgo-leaf oral liquor
Mustofa et al. Oral Administration of Moringa Leaf Ethanol Extract (Moringa Oleifera) for 14 Days Protects The Liver of Male White Rats (Rattus norvegicus) from Acute Damage Caused by High Doses of Paracetamol
KR100977583B1 (en) Ethanol extracts and caffeic acid from Ocnanthe javanica DC. having hepatoprotective effect, the method for preparing thereof and functional foodstuff comprising the same
DE102004004034A1 (en) onion extracts
Ominyi et al. Ameliorative effects of aqueous seed-extract of Dacryodes edulis on doxorubicin-induced cardiac tissue damage in albino rats

Legal Events

Date Code Title Description
A201 Request for examination
N231 Notification of change of applicant
E902 Notification of reason for refusal
A107 Divisional application of patent
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20131128

Year of fee payment: 16

FPAY Annual fee payment

Payment date: 20141226

Year of fee payment: 17

FPAY Annual fee payment

Payment date: 20151228

Year of fee payment: 18

EXPY Expiration of term